Please login to the form below

Not currently logged in
Email:
Password:

monoclonal antibody

This page shows the latest monoclonal antibody news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug

AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug

Enhertu belongs to a class of therapies called antibody drug conjugates (ADC), and consists of a HER2 monoclonal antibody chemically linked to a cell-killing chemotherapy drug.

Latest news

More from news
Approximately 4 fully matching, plus 345 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 36 partially matching documents found.

Latest appointments

  • Neurimmune appoints chief business officer Neurimmune appoints chief business officer

    Fabian Buller will further drive the biopharma’s growth strategy. Monoclonal antibody-focused Neurimmune has appointed Fabian Buller into the newly created role of chief business officer.

  • PharmaLex appoints Zabin Younes as associate director PharmaLex appoints Zabin Younes as associate director

    With experience spanning over 15 years, Younes’ expertise includes CMC regulatory strategies, monoclonal antibody biosimilars, developing and implementing global regulatory strategies, scientific advice and pre-submission activities.

  • Dr Arndt Schottelius to lead Kymab’s R&D Dr Arndt Schottelius to lead Kymab’s R&D

    Dr Schottelius will take on responsibility for the human monoclonal antibody specialist's R&D activities, including pre-clinical and clinical developments, from May this year. ... He joins from MorphoSys, where he has been chief development officer since

  • F-star appoints GSK's Neil Brewis F-star appoints GSK's Neil Brewis

    Cambridge-based antibody research company F-Star has appointed Dr Neil Brewis as chief scientific officer. ... Brewis joins from GlaxoSmithKline where he served as vice president and head head of biopharmaceutical research, leading a global team of 300

  • Novo's Wagtmann joins Innate as chief scientific officer Novo's Wagtmann joins Innate as chief scientific officer

    He is familiar with Innate through its collaboration with Novo on immunotherapies, including IPH2201, a monoclonal antibody targeting NKG2A in development to treat patients with inflammatory conditions.

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...